Mergers & acquisitions
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.
Life sciences giant Johnson & Johnson may be shopping around its sterilization products division.
Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Hayao will also form a JV with GNC to make and distribute GNC supplements in China.
The acquisition will strengthen Charles River’s position as a global early-stage CRO, expanding its client base and service portfolio.
According to sources reported by Reuters, potential buyers have been winnowed down to two pharma companies, three private equity funds, and a consortium of buyers.
PRESS RELEASES